Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits.

Frontiers in immunology - 1 Jan 2023

Wang Yixuan, Wang Jiayin, Fang Wenfeng, Xiao Xiao, Wang Quan, Zhao Jian, Liu Jingjing, Yang Shuanying, Liu Yuqian, Lai Xin, Song Xiaofeng

Abstract excerpt

A high tumor mutation burden (TMB) is known to drive the response to immune checkpoint inhibitors (ICI) and is associated with favorable prognoses. However, because it is a one-dimensional numerical representation of non-synonymous genetic alterations, TMB suffers from clinical challenges due to its equal quantification. Since not all mutations elicit the same antitumor rejection, the effect on immunity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Colorectal Cancer Treatments and Studies

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37234148
DOI: 10.3389/fimmu.2023.1151755
PMCID: PMC10208409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits.PMID 37234148Read ↗

THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data.Semantic proximity Read ↗

TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds.Semantic proximity Read ↗

Explainable machine learning identifies features and thresholds predictive of immunotherapy responseSemantic proximity Read ↗

AlphaMissense pathogenicity scores predict response to immunotherapy and enhances the predictive capability of tumor mutation burdenSemantic proximity Read ↗

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read ↗

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read ↗

Generalizable AI predicts immunotherapy outcomes across cancers and treatmentsSemantic proximity Read ↗

NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.Semantic proximity Read ↗

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Semantic proximity Read ↗

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read ↗

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Semantic proximity Read ↗

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.